Opinion|Videos|April 25, 2024
FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC
Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA granted fast track designation to MC001 for pancreatic cancer.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The EMA's CHMP recommended approval of daraxonrasib for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.
VS-7375 produced a responses previously treated metastatic pancreatic ductal adenocarcinoma.
The resubmission follows a third complete response letter issued in July 2026 that cited manufacturing deficiencies rather than efficacy or safety concerns.
The FDA has granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5